Table 2.
Resume of miRNAs based therapies targeting cardiomyocytes hypertrophy and fibrosis. The oligonucleotide modification, miRNA, the model used in the study, and the obtained result are depicted. LNA: locked nucleic acid.
| Oligonucleotide modification | miRNA | Model | Result | Ref. | |
|---|---|---|---|---|---|
| AntimiR | AntagomiR | miR-133 | C57BL/6 mice | Repression resulted in cardiac hypertrophic phenotype | [46] |
| AntagomiR | miR-21 | Heart failure induced by pressure overload mice | Repression reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis, and attenuates cardiac dysfunction |
[66] | |
| AntagomiR | miR-132 | Heart failure induced by pressure overload mice | Repression rescues heart hypertrophic phenotype | [67] | |
| LNA-modified oligonucleotide | miR-208a | Diastolic heart failure rats | Repression resulted in reduction of cardiac remodeling | [68] | |
|
| |||||
| RNA-mimic | Adenoviral vector containing miR-133a-2 precursor sequence |
miR-133 | AKT induced heart hypertrophy mice | Overexpression resulted in attenuation of cardiac hypertrophic phenotype | [46] |